# Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

> **NCT03432598** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 54 (actual)

## Conditions studied

- Locally Advanced Lung Cancer; Metastatic Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Etoposide
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03432598
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-24
- **Primary completion:** 2019-02-25
- **Final completion:** 2020-12-21
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432598, "Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03432598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*